NCT01155635

Carvedilol Post-intervention Long-term Administration in Large-scale Trial

Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 801 (actual)
• Sponsor: Takeshi Morimoto · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether beta-blocker therapy improves 6-year clinical outcomes in patients with ST-segment elevation acute myocardial infarction and preserved left ventricular ejection fraction after primary percutaneous coronary intervention.

Detailed description

Beta-blocker therapy is recommended after ST-segment elevation acute myocardial infarction (STEMI) in the current guidelines although its efficacy in those patients who have undergone primary percutaneous coronary intervention (PCI) has not been adequately evaluated. The purpose of this study is to evaluate whether beta-blocker, carvedilol improves 6-year clinical outcomes in patients with STEMI and preserved left ventricular ejection fraction after primary PCI. The design of this study is multicenter, open-label, randomized controlled trial enrolling 1300 patients without any exclusion criteria.

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Carvedilol	Use of Carvedilol with any dose
DRUG	No Carvedilol	No use of Carvedilol

Timeline

• Start date: 2010-07-01
• Primary completion: 2015-06-01
• Completion: 2017-03-01
• First posted: 2010-07-02
• Last updated: 2017-06-27

Locations

1 site across 1 country: Japan